Expert Interview
Discussing the use of Uplinza in IgG4-RD and the results from the Phase 3 INDIGO trail evaluating Zenas Biopharma's obexelimab
Ticker(s): ZBIO, AMGNInstitution: Stanford
- Associate Division Chief in the Division of Immunology and Rheumatology at Stanford University
- Internationally recognized expert in IgG4-related disease, as well as the Co-Founder and Co-Director of the Stanford Multidisciplinary Sarcoidosis Program.
- Has designed and led investigator-initiated and industry sponsored clinical trials in IgG4-related disease, sarcoidosis, Sjogren's disease, and rheumatoid arthritis
How many IgG4-RD patients do you manage?
Added By: wilson_adminWhat is your current use of Uplinza?
Added By: wilson_adminHow does obexelimab compare to SoC in your opinion?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
